Date: 2015-04-30
Type of information: Nomination
Compound:
Company: Keryx Biopharmaceuticals (USA - NY)
Therapeutic area: Renal diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 30, 2015, Keryx Biopharmaceuticals, a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease announced the completion of the previously announced transition of the CEO role from Ron Bentsur to Greg Madison. As per Mr. Bentsur\'s employment agreement, Mr. Bentsur will also be stepping down from the Company\'s Board of Directors, which will be reduced to seven members. * On March 10, 2015, Keryx Biopharmaceuticals announced the appointment of Mr. Greg Madison, the Company\'s President and Chief Operating Officer and incoming Chief Executive Officer, to its Board of Directors, effective March 10, 2015. With the addition of Mr. Madison to Keryx\'s Board, the Company has increased the size of its Board to 8 members. Mr. Madison joined Keryx in February 2014 and is currently the Company\'s President and Chief Operating Officer, and will transition to the role of Chief Executive Officer by the end of May 2015. Mr. Madison has more than 20 years of experience in the US pharmaceutical industry. Mr. Madison previously served as Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals (AMAG), where in 2013, he led the team to significant growth in net revenues. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products with combined revenues exceeding $1 billion. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.
Financial terms:
Latest news:
